Barozzi et al (2002) reported that TGF-α, MMP-2 and IGF-II seem to be suitable candidates for a selective panel of markers designed to provide significant information with respect to the current pathologic staging system for patients with colorectal carcinoma. This evidence concerns the gene TGFA and colorectal carcinoma.